Hiroaki Matsubara, a former Kyoto Prefectural University cardiology researcher who resigned last year following an investigation, has had another paper retracted, his ninth.
The American Heart Association (AHA) is retracting five studies by Hiroaki Matsubara, a former Kyoto Prefectural University cardiology researcher, that it had subjected to an expression of concern last year.
Hiroaki Matsubara, a leading Japanese cardiology researcher who has had three papers retracted and another five subject to expressions of concern, has resigned from Kyoto Prefectural University, according to local media.
Mainichi Shimbun reports — according to our roughest of (Google) translations — that Kyoto Prefectural University accepted Matsubara’s resignation following an investigation. That investigation — which the university had told us about last year — revealed serious problems with 27 studies.
The American Heart Association, which publishes a number of journals, has issued an Expression of Concern about five papers in three of their publications, following allegations of image manipulation. All of the papers include Hiroaki Matsubara, of Kyoto Prefectural University, as a co-author.
The notice begins:
It has come to the attention of the American Heart Association (AHA), in a public manner, that there are questions concerning a number of figures in several AHA journals’ articles…
The “public manner” was three posts last year on the Abnormal Science blog, available here, here and here, alleging that images were manipulated in the manuscripts, and that histology slides were reused.
The notice continues: Read the rest of this entry »
A second paper about a major randomized trial in Japanese patients with heart disease is being retracted, after an investigation reportedly found multiple problems with the paper.
As predicted by Pharma Japan, Hypertension Research is retracting a 2011 paper, already the subject of two errata. Although a spokesperson said she couldn’t say why the paper was being retracted, as the notice was still in production, editor Toshihiko Ishimitsu told us: Read the rest of this entry »
Frequent Retraction Watch subject Hiroaki Matsubara resigned his post at Kyoto Prefectural University in 2013, after his work on valsartan was shown to be riddled with data errors and undisclosed conflicts of interest.
Also that year, suspicions about Chiba University hypertension researcher Issei Komuro’s work were first raised by an anonymous blog, which detailed numerous image manipulations in the researcher’s published works. Komuro, who frequently collaborated with Matsubara, has been a senior author on a number of valsartan papers, including the now-retracted one, which reported the results of Novartis-sponsored Valsartan Amlodipine Randomized Trial in 2011 without reporting the Novartis funding.
The Lancet has retracted a study of Novartis’ blood pressure drug valsartan (Diovan) that has been subject to an investigation following the retraction of a related study earlier this year.
As Larry Husten, who first reported the retraction at Forbes, notes, the notice for 2009’s “Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study,” which appeared in the European Heart Journal, says very little: Read the rest of this entry »
The Circulation Journal, the official organ of the Japanese Circulation Society, is retracting two papers by Hiroaki Matsubara, lead researcher on the Kyoto Heart Study, for unreliable findings. Matsubara’s institution, Kyoto Prefectural University, confirmed to us last March that it was investigating the prominent cardiologist.
The work of Matsubara came into question last year when the American Heart Association issued an expression of concern for five papers the society published in its journals. Larry Husten, at Forbes/CardioBrief, reports today that the two retracted articles were “Effects of Valsartan on Cardiovascular Morbidity and Mortality in High-Risk Hypertensive Patients With New-Onset Diabetes Mellitus: Sub-Analysis of the KYOTO HEART Study,” published in September 2012; and “Enhanced cardiovascular protective effects of valsartan in high-risk hypertensive patients with left ventricular hypertrophy: Sub-analysis of the KYOTO HEART study,” which appeared in March 2011.